DNMT3A loss drives a HIF-1-dependent synthetic lethality to HDAC6 inhibition in non-small cell lung cancer.
Zhang J, Zhao Y, Liang R, Zhou X, Wang Z, Yang C, Gao L, Zheng Y, Shao H, Su Y, Cui W, Jia L, Yang J, Wu C, Wang L.
Zhang J, et al. Among authors: yang c.
Acta Pharm Sin B. 2024 Dec;14(12):5219-5234. doi: 10.1016/j.apsb.2024.08.025. Epub 2024 Sep 2.
Acta Pharm Sin B. 2024.
PMID: 39807333
Free PMC article.